Aging and chronic kidney disease mineral and bone disorder (CKD-MBD) interact to worsen bone health, vascular calcification, and frailty in older patients. The altered FGF23-Klotho axis and disrupted mineral homeostasis emphasize the need for early interventions to mitigate fractures and cardiovascular complications in this vulnerable population. This review provides an updated overview of the current knowledge on CKD-MBD in older patients.

CKD-MBD exacerbates bone fragility and vascular calcification in older populations. Early vascular aging and cognitive decline are associated with increased mortality. Disruptions in calcium, phosphate, and vitamin D homeostasis accelerate bone loss and fracture risk, whereas secondary hyperparathyroidism worsens cardiovascular outcomes. Additionally, polypharmacy, sarcopenia, and cognitive impairment further intensified the clinical burden in aging CKD patients.

Aging potentially worsens CKD-MBD, vascular calcification, and cardiovascular disease in older patients. This growing field offers promising opportunities for further research to enhance understanding, improve bone health outcomes, and reduce fracture risk.

Dual-energy X-ray absorptiometry (DXA) T -scores have been shown to predict fragility fractures in population-based studies. Recently, a novel MRI-based vertebral bone quality (VBQ) score has been proposed, showing better predictability for fragility fractures compared with DXA T -scores. The aim of this study was to explore the correlation between VBQ scores and DXA T -scores and to determine the impact of VBQ scores on the risk of subsequent fragility fractures after cement augmentation for osteoporotic vertebral compression fracture (OVCF).

Between January and December 2018, 251 consecutive patients who received cement augmentation for OVCF were included in the study. VBQ scores were calculated using noncontrast T1-weighted MRI. Correlations between VBQ and T -scores were assessed. Patients were divided into 2 groups based on the presence or absence of subsequent fragility fractures after cement augmentation: (1) no Subsequent fracture group and (2) subsequent fracture group. Comparisons between the groups were conducted, and risk factors of subsequent fractures were evaluated using multivariable logistic regression analysis.

Of the patients, 42 (16.7%) experienced subsequent fractures after cement augmentation. The VBQ score showed moderate correlations with the T -score of the hip (r = -0.523, P < .001) and the T -score of the lumbar spine (r = -0.383, P < .001). The subsequent fracture group had a significantly higher VBQ score (4.02 ± 0.56 vs 3.52 ± 0.62, P < .001) and a worse T -score of hip (-3.06 ± 1.28 vs -2.42 ± 0.98, P = .004). In the multivariable analysis, the VBQ score was the only independent predictor of subsequent fractures with 2.799 odds ratio (1.342 to 5.841, P = .006).

In patients who received cement augmentation for OVCF, the VBQ score is significantly correlated with the DXA T -score and may be a more reliable predictor of subsequent fragility fractures.

The purpose of the study was to evaluate trabecular bone score (TBS) technology for orthopedic application (TBSortho) as a predictor of a screw pull-out strength in a cadaveric model. This study finds that TBSortho correlates more strongly with the screw pull-out strength compared to cortical density, computed tomography (CT) Hounsfield units (HU), and dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD).

Patient bone quality impacts the mechanical strength of surgical fixation constructs. Preoperative assessments of bone quality and the potential for a screw pull-out are important for surgical planning as well as postoperative rehabilitation protocols. Previous work has correlated the screw pull-out strength with the screw insertional torque, cortical thickness, and CT HU. TBS is a gray-level textural metric that can be extracted from a two-dimensional DXA scan, improves fracture prediction, and may evaluate the mechanical competence of both the cortical and trabecular bones. The purpose of the study was to evaluate TBS technology for TBSortho as a predictor of the screw pull-out strength in a cadaveric model.

Twenty paired, fresh-frozen cadaver femurs stripped of soft tissue were obtained (5 M, 5 F specimens, age range of 56-96 years). Standard clinical femur CT were performed to obtain HU, cortical thickness, and cortical density. DXA was also performed using a novel analysis technique as distal femur DXA is not routinely acquired clinically. DXA data were used to generate TBSortho values in two distal femur regions of interest. All femurs then underwent a screw pull-out testing with five lateral distal femoral 5-mm locking screws (n = 100 screws total). The correlation coefficient from Spearman tests and R-squared of the fixed effects from the linear mixed effects models were calculated.

TBSortho was found to correlate most strongly of CT and DXA measures with the screw pull-out strength, having marginal R2 and standardized beta of 0.75 and 0.87 in the proximal screw cluster and 0.67 and 0.83 in the distal screw cluster, respectively. TBSortho accounted for 75% variance in the pull-out strength. CT HU and DXA bone mineral density (BMD) did not have a statistically significant correlation with the screw pull-out strength.

This study finds that TBSortho correlates more strongly with the screw pull out strength in a cadaveric distal femur model compared to cortical density, CT HU, and DXA BMD. These preliminary results suggest that TBSortho may be a valuable tool to model mechanical integrity of bone preoperatively.

Chronic use of proton pump inhibitors (PPIs) has been associated with an increase in bone fragility. However, evidence on the effect of chronic PPI use on bone density is conflicting, and data on bone microarchitectural quality are scarce.

The primary aim of this study was to evaluate whether trabecular bone microarchitecture, assessed by trabecular bone score (TBS), is altered in chronic PPI users. The association between PPI use and bone density was also evaluated as a secondary endpoint.

We extracted individual patient data from the 2005 to 2008 cycles of the population-based National Health and Nutrition Examination Survey (NHANES), in which lumbar spine dual-energy X-ray absorptiometry scans were acquired. TBS values were calculated from dual-energy X-ray absorptiometry images using a dedicated software. Multivariable linear regression analyses stratified by sex were performed to evaluate the association of chronic PPI use with TBS and bone mineral density (BMD), adjusting for relevant confounders.

A total of 7478 subjects were included (3961 men, 3517 women). After adjustment for relevant confounders, chronic PPI use was associated with a worse bone health profile in men, with lower TBS (-0.039; 95% CI, -0.058 to -0.020; P < .001), lumbar spine T-score (-0.27; 95% CI, -0.51 to -0.04; P = .023), total hip T-score (-0.21; 95% CI, -0.41 to -0.01; P = .041), and femoral neck T-score (-0.22; 95% CI, -0.44 to -0.00; P = .047). Notably, the association between chronic PPI use and degraded TBS remained statistically significant even after further adjustment for BMD at lumbar spine and femoral neck (-0.026; 95% CI, -0.039 to -0.012; P = .001). In contrast, no significant association was observed between chronic PPI use and either TBS or BMD in women.

Chronic PPI use is associated with degraded trabecular bone quality in men, even after adjustment for BMD. No association was observed in women.

Dual-energy X-ray absorptiometry (DXA) is an established method for osteoporosis screening and treatment monitoring, providing results that predict fracture risk. DXA is used not only to measure bone mineral density (BMD) in various anatomic sites, but also to perform vertebral fracture analysis, trabecular bone score (TBS) determination, and whole-body composition analysis. While DXA is central in osteoporosis screening, the test has limitations, and other factors beyond BMD measurements must be considered when planning treatments and follow-up strategies. For example, sex, race and ethnicity, prior fragility fractures, glucocorticoid use, and prior falls, all affect fracture risk. Despite a growing population of older individuals and growing evidence of variations in fracture risk, osteoporosis screening recommendations have not evolved significantly. Moreover, despite existence of screening recommendations, DXA remains underutilized, and osteoporosis underdiagnosed. This AJR Expert Panel Narrative Review discusses the current status of osteoporosis screening by DXA, addressing current practice recommendations, use of BMD results to guide risk predictions and management decisions, as well as challenges and limitations along with evolving solutions. Topics explored include DXA reporting and screening recommendations; fragility fracture risk assessment tools; role of TBS; race, ethnicity, and sex considerations; application in children; and CT-based BMD measurements and opportunistic screening.

Pregnancy and lactation-associated osteoporosis (PLO) is a rare bone disorder with insufficient understanding on its pathogenesis and treatments. We retrospectively investigated 22 Chinese PLO patients diagnosed in our hospital. Whole exome sequencing was performed in 14 patients, and responses to bisphosphonates treatment were evaluated. The mean age of the patients was 30.8 ± 4.4 years. The mean number of vertebral fractures per patient was 4.0 ± 2.6. The bone mineral density (BMD) Z-scores were - 2.9 ± 0.9 at the lumbar spine (LS), - 1.7 ± 0.7 at the femoral neck, and - 1.8 ± 0.7 at the total hip. Trabecular bone score Z-score was - 2.2 ± 0.8. Genetic analysis identified relevant variants (RVs) in 11 of 14 patients, predominantly in LRP5, WNT1, and COL1A1/A2. Patients with RVs had significantly greater height loss (3.6 ± 2.1 cm vs. 0 cm, p = 0.028). All patients received bisphosphonate therapy, during which increases in BMD primarily at the LS were observed: 13.5 ± 8.8%, 17.8 ± 14.7%, 22.0 ± 17.0%, 27.0 ± 14.1% and 35.1 ± 18.5% at the 6-, 12-, 24-, 36-, and 48-month follow-ups. Patients with RVs demonstrated LS BMD percentage changes of 40.1 ± 22.1% (vs. no RVs group 26.2 ± 14.8%, p = 0.57) after 48-month follow-ups. In conclusion, our study highlights the significant clinical burden of PLO. Genetic RVs are prevalent in Chinese PLO patients. After bisphosphonate treatment, there is a significant increase in BMD, especially in LS. Patients with RVs have the potential of more robust therapeutic response.

TBS usefulness in primary hyperparathyroidism (PHPT) management is uncertain. The primary aim was to evaluate the significance of performing Trabecular Bone Score (TBS) in addition to classical PHPT surgical recommendations. The explorative objective was to characterize bone quality in a cohort of patients with asymptomatic PHPT.

From 1/1/2021 to 5/31/2024, of 265 consecutively evaluated PHPT patients, 125 met inclusion and exclusion criteria. Patients underwent complete biochemical evaluation in the same laboratory, Dual Energy X-ray Absorptiometry (DXA) at three sites, TBS with the same densitometer, and renal ultrasound. We retrospectively applied to each patient all the criteria to recommend parathyroidectomy as per the Fifth International Workshop, adding also TBS ≤ 1.2.

Almost one-third of patients presented degraded TBS (≤ 1.2), 36.0% partially degraded TBS, and 31.2% preserved TBS (≥ 1.35). Mean TBS was partially degraded (1.286 ± 0.134). Osteoporotic patients had lower TBS than osteopenic patients (1.207 ± 0.101 vs. 1.27 9 ± 0.110; p <.001). Patients with degraded TBS had a greater number of fragility fractures than those with TBS > 1.2 (34.2% vs. 8.3%; p <.001). In the group of osteopenic patients (34.4%), 10/43 (23.3%) showed degraded TBS. 13 patients (10.4%) did not meet any surgical criteria, and of these, 3/13 (23.1%) had degraded TBS and were osteopenic.

More than one-fifth of patients who did not meet the current surgical recommendations presented degraded TBS and osteopenia. The combination of degraded TBS and osteopenia as a possible new surgical recommendation could increase the number of patients who might benefit from curative parathyroidectomy, with potential reduction of fracture risk.

Acromegaly is a chronic disease characterized by excessive growth hormone (GH) secretion leading to high insulin-like growth factor 1 (IGF- 1) levels. It results in systemic complications, including vertebral fractures (VFs), which impair quality of life. Bone mineral density (BMD) may not fully capture fracture risk, warranting further research into alternative predictors and mitigation strategies.

This study aimed to assess the prevalence of VFs in patients with acromegaly and identify associated risk factors.

A multicenter, cross-sectional study was conducted at three centers in Saudi Arabia and one in the United Arab Emirates (UAE). Data for patients with acromegaly evaluated between 2010 and 2024 were reviewed.

The cohort consisted of 101 patients (63% male) with a median age of 45 years and an median disease duration of 7 years. VFs were present in 10 patients, predominantly affecting the lumbar spine and were generally mild. Although not statistically significant, patients with VFs had longer disease durations. BMD measurements did not significantly differ between those with and without VFs; however, patients with VFs showed a trend toward lower trabecular bone score (TBS), suggesting compromised bone microarchitecture.

This study underscores the importance of comprehensive bone health assessment in patients with acromegaly incorporating BMD, TBS, and hormonal evaluations. Continuous long-term monitoring of bone health parameters is necessary in this population. Future research is needed to delineate risk factors associated with VFs.

Patients with haemophilia (PwH) might be restricted in physical activity (PA) depending on the severity phenotype. It is well-known that PA affects overall health including bone quality. This study aims to evaluate the level of PA within the different haemophilia severity phenotypes and to elaborate on the interplay of PA in regard to bone quality (bone mineral density (BMD) and trabecular bone score (TBS)) as well as lean mass.

This investigation was part of a large prospective single-center cohort study examining the relation between haemophilia and osteoporosis registered at clinicaltrials.gov (ID: NCT04524481). PwH underwent a dual x-ray screening using Horizon™ to examine BMD, TBS, and lean mass. Step activity was tracked electronically for seven consecutive days after clinical examination, supported by a self-reported activity diary for seven days. Handgrip strength was examined as an overall fitness proxy.

Data of 223 patients with either mild (N = 45), moderate (N = 46), or severe (N = 132) haemophilia A or B, aged 43.6 ± 15.6 years were analyzed. There was no significant difference in objective (p = 0.162) and subjective (p = 0.459) PA levels between severity phenotypes. The most frequent type of PA in all severities was walking (n = 72, 53.3%) and cycling (n = 60, 44.4%). Step activity positively correlated with TBS (rho = 0.202, p = 0.005) and lean mass positively correlated with BMD (rho = 0.309, p < 0.001). Handgrip strength correlated with BMD (rho = 0.361, p < 0.001) as well as TBS (rho = 0.221, p = 0.021) and lean mass (rho = 0.287, p = 0.003).

PA does not differ significantly between the severity phenotypes. The majority of PwH in all severity phenotypes performed low-impact PA, which is most likely insufficient to positively affect BMD. However, handgrip strength correlates with BMD and TBS. Despite restrictions in movement function or reduced BMD, it is of major importance to promote PA to maintain a healthy or even increase bone quality.

Impaired bone health is a common morbidity in Rett syndrome (RTT). We aimed to assess lumbar bone mineral density (BMD) and trabecular bone score (TBS) in females with RTT, and to evaluate the effectiveness of bisphosphonate treatment.

This retrospective study included 40 females with RTT, aged 5-22 years, who underwent dual-energy X-ray absorptiometry (DXA) scans during 2019-2024 at a national center for RTT. Data collected included medical treatment, anthropometric measurements, and functional scores.

The median age at the first DXA scan was 10.8 years. The mean L1-4 BMD Z-score was -2.1 ± 1.4, and the mean TBS Z-score was -0.4 ± 1.3. The L1-4 BMD Z-score correlated with height (r = 0.407, p = 0.009), weight (r = 0.551, p < 0.001), BMI (r = 0.644, p < 0.001), and TBS Z-scores (r = 0.594, p = 0.009). Poor L1-4 BMD Z-scores were associated with poor mobility scores (p = 0.05) and valproate treatment (p = 0.016). Nine patients (23%) received zoledronate, for a mean 2 years. The mean age at zoledronate initiation was 9.7 ± 2.3 years. Four completed two DXA scans (pre- and post-treatment); the mean BMD Z-score improved from -2.2 ± 0.9 to -1.4 ± 0.9 after treatment.

Females with RTT have reduced lumbar BMD, which was associated with anthropometric factors, TBS, mobility, and valproate use. Zoledronate may be effective for some patients.

In a retrospective study of 40 females with Rett syndrome (RTT), low bone mineral density (BMD) correlated with lower anthropometric measurements, impaired mobility, and valproic acid use. The association between BMD and trabecular bone score (TBS) in the context of RTT is a novel finding. Our preliminary data support the effectiveness and safety of zoledronate for treating osteoporosis in patients with RTT. Our findings are important in light of the increasing life expectancy of individuals with RTT, and the consequent need to prioritize bone health in this population.

This study evaluates TBS for estimating bone microarchitecture in ESRD patients using HR-pQCT as the reference technique.

TBS correlates significantly with vBMD and bone microarchitecture, unlike aBMD.

TBS may complement bone health assessment in ESRD patients by offering additional information alongside aBMD.

Given the high fracture risk, non-invasive techniques for assessing bone fragility in chronic kidney disease (CKD) remain important. Trabecular bone score (TBS) may provide additional information that could help guide treatment and follow-up decisions. The aim of this study is to investigate whether TBS reflects bone microarchitecture in end-stage renal disease (ESRD) patients, using high-resolution peripheral quantitative computed tomography (HR-pQCT) as the reference technique. Additionally, we aim to identify parameters associated with a low TBS.

Seventy-five ESRD patients were included at the time of kidney transplantation (KTx). Areal bone mineral density (aBMD) was analyzed using dual-energy X-ray absorptiometry (DXA). TBS was assessed from the L1-L4 area during DXA. Volumetric BMD (vBMD) and bone microarchitecture at tibia and radius sites were analyzed using HR-pQCT.

In ESRD patients, those with TBS < 1.370 were older and had a higher body mass index (BMI). In contrast to T-score-based classification (≤ -2.5 or > -2.5), low TBS was linked to significantly lower trabecular and cortical vBMD, reduced trabecular bone volume fraction (BV/TV) and trabecular number (Tb.N), and increased trabecular separation (Tb.Sp). In multivariate analysis, older age, higher BMI, and lower Tb.N remained independently associated with low TBS, while no HR-pQCT parameters were linked to low aBMD (T-score ≤ -2.5).

TBS correlates with both trabecular and cortical parameters measured by HR-pQCT, potentially offering a complementary perspective on bone microstructure compared to aBMD. At the time of KTx, a low TBS appears to better discriminate patients with significantly lower vBMD than aBMD alone.

To evaluate the trabecular bone score (TBS) Z scores in long-distance runners with bone stress injuries (BSIs) in whom the bone mineral density (BMD) Z score is more than -1.0 (Aim 1) and whether the number of runners with abnormal TBS Z scores would be higher in those with BSI in trabecular-rich sites as compared with cortical-rich sites (Aim 2).

Retrospective cohort study.

Institutional sports medicine center.

We analyzed Z scores derived from the TBS and BMD in 44 long-distance runners aged 18 to 40 years who had sustained BSIs between 2017 and 2023 and undergone a dual-energy x-ray absorptiometry scan with reported TBS measurements within 1 year before or 2 years after their injuries.

Bone mineral density and TBS Z scores.

Evaluation of BMD and TBS Z scores in long-distance runners with BSIs, further stratified according to cortical-rich and trabecular-rich BSIs.

Bone mineral density assessments revealed an average Z score of -0.96 ± 0.99. In this cohort of 44 runners, 55% (n = 24) of runners were reported to have BMD Z score more than -1.0. Within this subgroup, 54% (n = 13) displayed abnormal TBS. Stratifying BSIs by trabecular- (n = 23) and cortical-rich (n = 19) sites, we found no significant difference in sex, mean BMD, or the number of runners with abnormal TBS between the 2 groups.

Trabecular bone score Z scores in sports medicine may provide complementary information to BMD in long-distance runners with BSI, particularly when the BMD Z scores are more than -1.0. However, further research is needed to validate the usefulness of TBS Z scores in this context.

Cohort study.

Retrospective Case Series, IV.

Lung transplant candidates routinely undergo dual-energy x-ray absorptiometry (DXA) screening due to increased risk of osteoporosis secondary to comorbidities and prolonged immunosuppression. Nonetheless, postoperative insufficiency fractures have been well documented, even in patients with normal bone mineral density (BMD). This study investigated the added value of trabecular bone score (TBS) as a complementary screening index of bone microarchitecture.

A retrospective review of 143 lung transplant candidates who underwent preoperative DXA screening was performed. TBS was calculated from DXA of the lumbar spine. DXA and TBS measurements were standardized using T-scores with reference to established population-based datasets.

Differences in the observed rates of osteopenia (36.4%), osteoporosis (11.2%), partially degraded bone (35.0%), and degraded bone (35.0%) were statistically significant (P < .001). Abnormal trabecular microarchitecture was significantly more prevalent than abnormal BMD (69.9% versus 47.6%; P < .001). TBS T-scores (mean = -1.98, SD = 1.39) were, on average, significantly lower than DXA T-scores (mean = -0.80, SD = 1.57; t[142] = 9.09; P < .001). Hispanic patients (mean = -1.25, SD = 1.28) had significantly lower DXA T-scores compared with White (mean = -0.28, SD = 1.14) or Black patients (mean = -0.30, SD = 1.31; F[2, 109] = 8.28; P < .001). By contrast, TBS T-scores did not differ by race or ethnicity (F[2, 109] = 0.26; P = .78).

Impaired trabecular microarchitecture is extremely common among lung transplant candidates, with a substantial proportion at risk of fracture through degraded bone despite normal BMD. TBS offers promise as a simple, robust, inexpensive, and noninvasive screening adjunct to DXA in this unique and vulnerable population.

The purpose of this study was to assess the anatomical size of proximal femur in South Korea. This study measured cortical thickness and cortical thickness index (CTI) based on computed tomography (CT) and additionally, evaluated the T-score and trabecular bone score (TBS) based on the dual energy X-ray absorptiometry (DXA).

This retrospective study is a cross-sectional study based on data from 600 patients aged from 20 to 93 years during the time from 2011 to 2021 were enrolled and selected the patients who did the examination of both pelvic CT and DXA scan. Age, sex, BMI, T-score, TBS, cortical thickness, CTI and the size of proximal femur were analyzed. Among these patients, 200 patients each corresponding to femoral neck fracture group(N = 200), trochanteric fracture group(N = 200), and non-fracture group(N = 200) were randomly selected and studied. The differences of three groups were compared statistically.

Mean outer diameter of proximal femur was 24.34 mm, inner diameter of proximal femur was 15.28 mm, cortical thickness was 4.55 mm and CTI was 0.37 at the lesser trochanter (LT) level. The outer diameter was 24.00 mm, inner diameter of proximal femur was 13.04 mm, cortical thickness was 4.97mm and CTI was 0.44 at 3cm below LT. In the hip fracture group, T-score of hip, outer diameter of proximal femur and cortical thickness at LT were lower than non-fracture group. BMI, T-score of spine, T-score of hip, inner diameter at 3cm below LT, CTI of LT and TBS were lower in femoral neck fracture group compared to the trochanteric fracture group.

Analysis of 600 patients of pelvic CT might be a representative of real size of proximal femur in South Korea. Outer diameter of proximal femur at LT and cortical thickness at LT level were significantly lower in hip fracture group. Narrower outer diameter of proximal femur and thinner cortical thickness at LT level from the CT might be a risk factor of hip fracture.

Hyponatremia is associated with increased risk of osteoporosis and fractures. The impact of hyponatremia on noninvasive indices of bone quality, however, is unknown.

To evaluate whether trabecular bone microarchitecture, assessed noninvasively by trabecular bone score (TBS), is altered in patients with hyponatremia.

We conducted a cross-sectional analysis of the population-based 2005-2008 cycles of the National Health and Nutrition Examination Survey, in which TBS measurement was performed. The main outcome measures were TBS values and bone mineral density (BMD) T-scores at the lumbar spine, total hip and femoral neck.

A total of 4204 subjects aged 50 years or older were included (4041 normonatremic, 163 hyponatremic-90.8% with mild hyponatremia). Univariate analyses did not show any difference in TBS between patients with and without hyponatremia (1.308 ± 0.145 vs 1.311 ± 0.141, P = .806). Hyponatremic subjects had lower BMD T-score at total hip (-0.70 ± 1.46 vs -0.13 ± 1.32, P < .001) and femoral neck (-1.11 ± 1.26 vs -0.72 ± 1.14, P = .004), while no difference was observed at lumbar spine (-0.27 ± 1.63 vs -0.31 ± 1.51, P = .772). After adjustment for relevant confounders, hyponatremia was confirmed as an independent predictor of lower BMD T-score at the total hip (β = -0.20, 95% confidence interval [CI]: [-0.39, -0.02], P = .029), while the significance was lost at the femoral neck (P = .308). Again, no association between hyponatremia and lumbar spine BMD (P = .236) or TBS (P = .346) was observed.

Hyponatremia, at least in mild forms, is not associated with a degradation of trabecular microarchitecture, assessed noninvasively by TBS. An independent association between hyponatremia and loss of bone mass is confirmed, particularly at the total hip.

Bone mineral density (BMD) is only one of several bone strength determinants affected by osteoporosis therapies. Trabecular Bone Score (TBS), a gray-level texture index determined from lumbar spine (LS) dual-X-ray absorptiometry scans, is an indirect measure of bone microarchitecture independent of and complementary to BMD and clinical risk factors. In the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk (ARCH), monthly subcutaneous romosozumab 210 mg for 12 mo followed by 24-mo open-label weekly oral alendronate 70 mg (romosozumab-to-alendronate) significantly reduced fracture risk compared to 36-mo alendronate alone in postmenopausal women with osteoporosis and prior fracture. This analysis evaluated tissue thickness-adjusted TBS (TBSTT) in a subgroup of patients from ARCH who had post-hoc TBS measurements at baseline and at least one post-baseline visit at months 12, 24, and 36. Baseline characteristics were similar between romosozumab-to-alendronate (n = 190) and alendronate alone (n = 188). Romosozumab led to significantly greater gains in TBSTT vs alendronate at month 12 (least squares mean difference, 3.6%), with greater gains maintained after transition to alendronate and persisting at months 24 (2.9%) and 36 (2.3%; all p<.001). Romosozumab-to-alendronate increased the percentage of individual patients with "normal" TBSTT from 28.9% at baseline to 48.1%, 43.9%, and 45.4% at months 12, 24, and 36, respectively, and decreased the percentage of individual patients with degraded TBSTT from 52.6% to 33.3%, 36.0%, and 33.5%, respectively (all p<.001). A similar but smaller trend was observed with alendronate alone from baseline through month 36 (p ≤.012). Changes in TBSTT and LS BMD were largely unrelated from baseline to month 12 (romosozumab-to-alendronate, r2 = 0.065; alendronate alone, r2 = 0.021) and month 36 (r2 = 0.058; r2 = 0.057, respectively). In postmenopausal women with osteoporosis and prior fracture, 12-mo romosozumab followed by 24-mo alendronate significantly improved bone microarchitecture estimated by TBSTT more than 36-mo alendronate alone.

Osteoporosis significantly affects older adults by reducing bone mass and increasing fracture risk, thereby impacting morbidity and mortality. This study aimed to investigate the relationship between bone mineral density (BMD), body mass index (BMI), and trabecular bone score (TBS) among middle-aged and older men with or without benign prostatic hyperplasia (BPH).

A retrospective study was conducted using health examination data from male participants aged 50-98 years collected at a regional hospital in southern Taiwan. Simple and multiple linear regression analyses were employed to examine the relationships between TBS and the independent variables. A total of 3714 middle-aged and older men were included in the analysis.

Findings indicated that higher BMI was associated with greater BMD; however, the relationship with TBS suggested potential bone quality degradation in cases of underweight and obesity. Multiple linear regression analysis demonstrated that age, waist circumference, BMD, underweight status, and obesity were significantly associated with TBS.

This study revealed the associative relationship between BMI and bone health: higher BMI was associated with increased bone density but also related to a decline in bone quality as measured by TBS, particularly in cases of obesity. These results emphasized the importance of managing BMI to optimize both bone density and quality, especially in middle-aged and older men with or at risk of BPH.

Trabecular bone score (TBS), a gray-level texture index derived from lumbar spine (LS) dual-energy x-ray absorptiometry (DXA) scans, is decreased in patients with diabetes and is associated with increased fracture risk, independent of areal bone mineral density (aBMD), but potentially influenced by abdominal fat tissue.

Evaluate effect of romosozumab (210 mg monthly) for 12 months followed by alendronate (70 mg weekly) for 24 months vs alendronate alone (70 mg weekly) for 36 months on LS aBMD and TBS in women with type 2 diabetes (T2D) enrolled in the ARCH study.

This post hoc analysis included women from ARCH who had T2D at baseline and LS DXA scans at baseline and ≥1 postbaseline visit (romosozumab-to-alendronate, n = 165; alendronate-to-alendronate, n = 195). aBMD and TBS (determined by an updated tissue thickness-adjusted TBS algorithm [TBSTT]) were assessed on LS DXA scans at baseline and ≥1 postbaseline visit (months 12, 24, and 36).

Romosozumab led to significantly greater gains in LS aBMD and TBSTT at month 12 vs alendronate, and the greater gains with romosozumab were maintained after transition to alendronate and persisted significantly at months 24 and 36 vs alendronate alone. TBSTT percentage changes weakly correlated to LS aBMD percentage changes from baseline to month 36 (romosozumab-to-alendronate, R2 = 0.1493; alendronate-to-alendronate, R2 = 0.0429).

In postmenopausal women with osteoporosis and T2D, 12 months of romosozumab followed by 24 months of alendronate vs alendronate alone significantly improved LS aBMD and TBSTT (independently of abdominal fat) and to a greater extent. Hence, romosozumab may improve bone strength in patients with T2D.

ClinicalTrials.gov-NCT01631214.

Gaucher disease is a rare lysosomal storage disorder characterized by the accumulation of glucocerebroside lipids within multiple organs due to a deficiency of the lysosomal enzyme (acid β-glucosidase). It is an inherited autosomal recessive disease. The onset of symptoms can vary depending on disease type and severity, with milder forms presenting in adulthood. The main clinical manifestations include cytopenia, splenomegaly, hepatomegaly, and bone lesions. GD is characterized by several bone manifestations, such as osteopenia/osteoporosis, focal lytic or sclerotic lesions, osteonecrosis acute or chronic bone pain, Erlenmeyer flask deformity, and subchondral joint collapse with secondary degenerative arthritis. In 70-100% of patients affected by Gaucher disease type 1, clinical or radiographic evidence of bone disease occurs. Among bone complications, osteoporosis is very common, but its etiopathogenesis in GD is not completely clear. Results deriving from experimental studies support the hypothesis that there is an aberrant activity of both osteoclasts and osteoblasts due to several factors, resulting in impaired bone turnover. Bone complications represent the main cause of pain, disability, and reduced quality of life in these patients. Therefore, there is a need to enhance awareness among physicians on the skeletal manifestations throughout life of GD patients, in order to improve diagnosis and management of bone complications. In particular, this narrative review focuses on risk of bone fragility in GD, etiopathogenetic hypotheses, epidemiological data, diagnosis, monitoring, and treatment of osteoporosis in patients suffering from Gaucher disease, specifying the challenges not yet addressed.

Background/Objectives: This study presents a novel approach, based on a combination of radiomic feature extraction, data resampling techniques, and machine learning algorithms, for the detection of degraded bone structures in Dual X-ray Absorptiometry (DXA) images. This comprehensive approach, which addresses the critical aspects of the problem, distinguishes this work from previous studies, improving the performance achieved by the most similar studies. The primary aim is to provide clinicians with an accessible tool for quality bone assessment, which is currently limited. Methods: A dataset of 1531 spine DXA images was automatically segmented and labelled based on Trabecular Bone Score (TBS) values. Radiomic features were extracted using Pyradiomics, and various resampling techniques were employed to address class imbalance. Three machine learning classifiers (Logistic Regression, Support Vector Machine (SVM), and XGBoost) were trained and evaluated using standard performance metrics. Results: The SVM classifier outperformed the other classifiers. The highest F-score of 97.5% was achieved using the Grey Level Dependence Matrix and Grey Level Run Length Matrix feature combination with SMOTEENN resampling, which proved to be the most effective resampling technique, while the undersampling method yielded the lowest performance. Conclusions: This research demonstrates the potential of radiomic texture features, resampling techniques, and machine learning methods for classifying DXA images into healthy or degraded bone structures, which potentially leads to improved clinical diagnosis and treatment.

This practice guideline serves as an update to the Canadian Association of Radiologists' 2013 Technical Standards for Bone Mineral Densitometry Reporting. It aims to align bone mineral density testing and reporting practices in Canada with current clinical best practices, including guidelines from Osteoporosis Canada and the International Society for Clinical Densitometry. Key updates include the endorsement of both FRAX and CAROC tools for evaluating fracture risk, guidance for analyzing male patients and transgender patients, and provision of clinical management guidance of relevance to BMD reporting harmonized with that of Osteoporosis Canada. The document emphasizes the importance of accurate data collection in fracture risk assessment and provides recommendations for reporting fracture risk, T-scores, and clinical management strategies. Additionally, it outlines indications for baseline BMD testing and reassessment timelines, aiming to facilitate appropriate patient management and enhance bone health outcomes. This guideline is intended to complement existing standards and support healthcare professionals in delivering optimal care for patients undergoing BMD testing in Canada.

Lipids increase osteoporosis and fracture risk, yet research on Atherogenic Index of Plasma (AIP), bone mineral density declines (BMD), and trabecular bone score (TBS) is limited. This study examined the relationships between AIP, TBS, and BMD in American adults using the National Health and Nutrition Examination Survey (NHANES) data, including the effect of obesity.

Based on data from 3,162 Americans, multivariable logistic regression and a generalized additive model (GAM) were used to analyze AIP, BMD, and TBS. Mediation studies assessed the impact of obesity (BMI) on these relationships. A threshold effect study identified turning points.

The average participant age was 47.5 ± 17 years. AIP showed no correlation with BMD after BMI adjustment but was significantly associated with lumbar spine and femoral neck BMD without BMI adjustment. AIP negatively correlated with TBS even after adjusting for covariates. The relationship between AIP and TBS was L-shaped, with a turning point at -0.17. BMI mediated the AIP-BMD relationship by 122.01-131.49% (P < 0.05).

This study found AIP levels associated with decreased TBS and increased BMD, influenced by obesity. AIP may be a valuable tool in evaluating bone metabolism, indicating high BMD but poor TBS, warranting further exploration.

With the increased life expectancy of people with cystic fibrosis (CF), clinical attention has focused on prevention and treatment of non-pulmonary comorbidities. CF-related bone disease (CFBD) is a common complication and leads to increased fracture rates. Dual energy X-ray absorptiometry (DXA) is the recommended and gold standard technique to identify and monitor bone health. However, DXA has limitations because of its two-dimensional nature. Complementary tools to DXA are available, such as trabecular bone score (TBS) and vertebral fracture assessment (VFA). Quantitative computed tomography (QCT), magnetic resonance imaging (MRI) and quantitative ultrasound (QUS) may also be useful.

DXA-derived reference data for visceral adipose tissue (VAT) and advanced hip analysis (AHA) parameters spanning the entire adult lifespan are limited. The purpose of this study was to develop age-, site- and sex-specific reference data for dual X-ray absorptiometry (DXA) -derived body composition, trabecular bone score (TBS) and advanced hip analysis (AHA) parameters across the adult lifespan. Adults (N = 908; female: 561 and male: 347) from Calgary and the surrounding area over the age of 20 years participated in this study. Participants received DXA scans of their hip (total hip [TH] and femoral neck [FN]), lumbar spine [LS], forearm [33 % site] and total body (iDXA, GE Lunar, GE Healthcare). Areal bone mineral density (aBMD, g/cm2) was captured at all sites, and body composition variables, including lean mass, fat mass and percent fat, were analyzed from the total body scan. VAT mass was assessed from total body DXA scans. Advanced hip analysis (AHA) was performed on hip scans and trabecular bone score (TBS) on the LS scans to assess bone quality. Site- and sex-specific centile curves and tables were generated using the Generalized Additive Models for Location, Scale, and Shape (GAMLSS) method. Clinicians and researchers can use these Canadian reference data as a tool to assess body composition, TBS and AHA parameters across the adult lifespan.

Fabry disease (FD) is an inherited X-linked lysosomal storage disease characterized by increased risk of osteoporosis and fractures. The impact of FD on clinical measures of bone quality is unknown. This considered, aim of our study was to evaluate whether trabecular bone microarchitecture, measured by trabecular bone score (TBS), is altered in patients with FD compared to control subjects.

This retrospective monocentric study enrolled 14 patients (M/F 1/1, median age 46 [37-63] years, range 31-72 years) newly diagnosed with FD between January 2016 and July 2023 who underwent dual-energy X-ray absorptiometry (DXA) image at the time of diagnosis and 42 matched controls. In all subjects, data about bone mineral density (BMD) and lumbar spine TBS were collected and total calcium, parathyroid hormone (PTH), 25(OH) vitamin D, alkaline phosphatase (ALP), creatinine and estimated glomerular filtration rate (eGFR) were evaluated. In subjects with FD, globotriaosylsphingosine (lyso-Gb3), 24-hour proteinuria and albumin-creatinine ratio were also assessed.

Patients with FD presented significantly lower lumbar spine TBS (1.29 [1.22-1.38] vs. 1.42 [1.39-1.47], p < 0.001) and lower lumbar spine BMD (0.916 ± 0.166 vs. 1.031 ± 0.125 g/cm2, p = 0.008) compared to controls; moreover, FD was shown to be an independent risk factor for both low lumbar spine TBS (β = -0.118, p < 0.001) and BMD (β = -0.115, p = 0.009). No differences were found in serum calcium, ALP, 25(OH) vitamin D and eGFR in both groups, but FD patients had significantly higher PTH levels compared to controls (p = 0.016). Finally, 8 patients with FD presented either moderately or severely increased albuminuria and only 2 patients presented normal lyso-Gb3 levels.

Patients affected by FD present significantly lower lumbar spine TBS and BMD compared to controls. Our findings strongly support the importance of carrying out a thorough evaluation of bone status in all patients affected by FD at baseline.

There is a paucity of studies describing trabecular bone score (TBS) and bone mineral density (BMD) in kidney transplant (KT) recipients from developing countries.

This prospective observational study, from a tertiary teaching hospital in India assessed clinical, biochemical parameters including bone turnover markers and dual-energy X-ray absorptiometry (DXA) for BMD/TBS, hip structural analysis (HSA) and vertebral fracture assessment (VFA) at pre-KT, 3 months and 12 months post-KT.

A total of 53 KT recipients (90.6% living related) were recruited from August 2019 to March 2020 and followed till 1-year post-KT. The mean age was 33.9±10.4 years, 71.7% were males, and 11.5% had a history of pre-KT steroid use. Baseline fractures pre-KT as assessed by VFA were seen in 4 patients (7.5%). Mean BMD at spine and femoral neck and HSA variables at narrow neck and femoral shaft continued to decline till 3 months, but stabilised and reached pre-KT values 12 months post-KT. However, TBS and bone turn over markers continued to decline till 12 months post-KT (p value <0.001). New onset vertebral fractures were seen in 2(3.7%) and 1 patient (2.3%) at 3- and 12-months post-KT respectively. Pre-KT BMD significantly influenced bone health at 12 months post-KT, with patients in each quartile maintaining a similar trajectory over the follow up period (p < 0.001).

Despite significant improvement in kidney function following transplant, TBS and BMD of the spine significantly decreased mainly in the early post-KT period suggesting the effect of immunosuppressants on the bone. Strategies to improve bone health in KT patients are warranted.

Axial radiographic spondyloarthritis (r-axSpA) is a chronic inflammatory joint disease that leads to a considerable decline in the quality of life of patients by impairment of function and mobility, which, in turn, brings about a deterioration of both physical and mental health. Osteoporosis (OP) is a significant issue in the course of r-axSpA. Fractures resulting from OP complicate the treatment of the underlying disease and reduce the quality of life of patients. The aim of this paper is to discuss currently available diagnostic methods for OP and highlight why the gold standard for diagnosis - the assessment of bone mineral density via dual-energy X-ray absorptiometry - is not sufficient for patients with r-axSpA.

Thyroid hormone is a known pivotal factor that affects bone metabolism; however, whether bone microarchitecture is associated with thyroid hormone sensitivity is poorly understood. The trabecular bone score (TBS) serves as an essential indicator for assessing bone microarchitecture. This study aimed to investigate the relationship between sensitivity to thyroid hormones and TBS in euthyroid individuals.

This cross-sectional study involved 3320 euthyroid participants from the National Health and Nutrition Examination Survey (NHANES) 2007-2008. Data, including thyroid function, TBS and other related parameters, were extracted and analyzed. The indices of thyroid hormone sensitivity, including the thyrotropin thyroxine resistance index (TT4RI), thyroid-stimulating hormone index (TSHI), thyroid feedback quantile-based index (TFQI) and parametric thyroid feedback quantile-based index (PTFQI), were calculated. Greater values of these indicators indicated a greater degree of impaired thyroid hormone sensitivity.

Impaired sensitivity to thyroid hormones was associated with degraded bone microarchitecture following adjustments for confounding variables (TT4RI: P = 0.005, TSHI: P = 0.008, TFQI: P = 0.003 and PTFQI: P = 0.006). The restricted cubic spline model demonstrated a positive relationship between TT4RI, TSHI, TFQI, PTFQI and degraded bone microarchitecture. Similar findings were observed in the analysis of subgroups stratified by age, sex, race, diabetes status, hypertension status and hyperuricemia status.

In euthyroid individuals, impaired sensitivity to thyroid hormones is associated with degraded bone microarchitecture. However, further studies are required to confirm this relationship.

Osteogenesis imperfecta (OI) is a congenital skeletal disorder characterized by bone fragility. Bisphosphonates (BISs) have become the mainstream treatment in children with OI. However, an optimal treatment protocol has not yet been established, while BIS treatment tends to be administered to normalize bone mineral density (BMD). Bone quality is an important component of bone strength. The trabecular bone score (TBS) is a quantitative measure of the microstructure that affects bone quality. This study investigated the TBS during BIS treatment in children with OI.

Twenty-nine children with OI were enrolled and classified into two groups: mild (type 1) and moderate to severe (types 3 and 4). Dual-energy x-ray absorptiometry images were retrospectively analyzed for TBS calculation. The relationship between the areal BMD (aBMD), its Z-score, height-adjusted BMD (BMDHAZ) Z-score, TBS, and TBS Z-score with the treatment duration was assessed for each group.

In the mild group, the aBMD, its Z-score, and BMDHAZ Z-score showed a significant positive correlation with treatment duration (r = 0.68, 0.68, 0.72, respectively, p < 0.01). The TBS Z-score tended to increase with treatment duration, albeit without reaching significance. In the moderate to severe group, the TBS Z-score showed a significant positive correlation with treatment duration (r = 0.48, p < 0.01), in contrast to the aBMD Z-score, which did not increase. Finally, the BMDHAZ Z-score only showed a weak positive correlation with treatment duration (r = 0.37, p < 0.01).

Because BIS affect the BMD and TBS differently based on the severity of OI, treatment goals may need to be stratified by disease severity.

Pituitary hormones play a crucial role in regulating skeletal physiology, and skeletal fragility is a frequent complication of pituitary diseases. The ability to predict the risk of fracture events is crucial for guiding therapeutic decisions; however, in patients with pituitary diseases, fracture risk estimation is particularly challenging. Compared to primary osteoporosis, the evaluation of bone mineral density by dual X-ray absorptiometry is much less informative about fracture risk. Moreover, the reliability of standard fracture risk calculators does not have strong validations in this setting. Morphometric vertebral assessment is currently the cornerstone in the assessment of skeletal fragility in patients with pituitary diseases, as prevalent fractures remain the strongest predictor of future fracture events. In recent years, new tools for evaluating bone quality have shown promising results in assessing bone impairment in patients with pituitary diseases, but most available data are cross-sectional, and evidence regarding the prediction of incident fractures is still scarce. Of note, apart from measures of bone density and bone quality, the estimation of fracture risk in the context of pituitary hyperfunction or hypofunction cannot ignore the evaluation of factors related to the underlying disease, such as its severity and duration, as well as the specific therapies implemented for its treatment. Aim of this review is to provide an up-to-date overview of all major evidence regarding fracture risk prediction in patients with pituitary disease, highlighting the need for a tailored approach that critically integrates all clinical, biochemical, and instrumental data according to the specificities of each disease.

Primary hyperparathyroidism (PHPT) is a disorder marked by chronic parathyroid hormone hypersecretion, which affects bone turnover and remodelling processes. With a loss of bone density and an increase in bone porosity, the cortical compartment is most severely impacted. The study's goal is to assess PHPT's effects on the volumetric bone mineral density (vBMD) of the femur's trabecular compartment as well as the vBMD and thickness of the cortical bone.

This is a retrospective case-control study, valuating age, biochemical doses, anthropometric measurements, and bone measurements. Between 2011 and 2016, 74 Caucasian Italian women and men with PHPT were sought out. Biochemical analyses were added to bone mineral density (BMD) values found in the lumbar spine and femoral neck. Proximal femur parameters such as cortical and trabecular volumetric (v) BMD, cortical thickness (CTh) and surface (s) BMD were analyzed by 3D-DXA software (3D-SHAPER Medical, Spain).

The findings showed a negative correlation between PHPT patients and controls, which was equally affecting the cortical and trabecular compartments. This correlation was especially evident in the areal BMD (aBMD) and vBMD measurements. Nonetheless, no appreciable correlation was found between the cortical level and the thickness of the cortical bone.

Parathormone (PHT) levels had an adverse effect on the cortical, trabecular volumetric density in this investigation, as was expected. Cortical thickness, however, is unaffected significantly. The literature and these findings are consistent.

There is abundant evidence that bone mineral content is highly heritable, while the heritability of bone quality (i.e. trabecular bone score [TBS] and quantitative ultrasound index [QUI]) is rarely investigated. We aimed to disentangle the role of genetic, shared and unique environmental factors on TBS and QUI among Hungarian twins. Our study includes 82 twin (48 monozygotic, 33 same-sex dizygotic) pairs from the Hungarian Twin Registry. TBS was determined by DXA, QUI by calcaneal bone ultrasound. To estimate the genetic and environmental effects, we utilized ACE-variance decomposition. For the unadjusted model of TBS, an AE model provided the best fit with > 80% additive genetic heritability. Adjustment for age, sex, BMI and smoking status improved model fit with 48.0% of total variance explained by independent variables. Furthermore, there was a strong dominant genetic effect (73.7%). In contrast, unadjusted and adjusted models for QUI showed an AE structure. Adjustments improved model fit and 25.7% of the total variance was explained by independent variables. Altogether 70-90% of the variance in QUI was related to additive genetic influences. We found a strong genetic heritability of bone quality in unadjusted models. Half of the variance of TBS was explained by age, sex and BMI. Furthermore, the adjusted model suggested that the genetic component of TBS could be dominant or an epistasis could be present. In contrast, independent variables explained only a quarter of the variance of QUI and the additive heritability explained more than half of all the variance.

While only a few postmenopausal women exhibit biochemical signs of hypovitaminosis D, it has been shown that vitamin D insufficiency has detrimental effects on the overall skeleton mineralization, bone turnover rate, and may be a significant risk factor for osteoporosis and fracture. We evaluated the concurrent effect of Vitamin D levels and biochemical markers of bone turnover on bone health of postmenopausal women.

The present study was conducted within the framework of the Bushehr Elderly Health (BEH) program, a population-based prospective cohort study being conducted in Bushehr, a southern province of Iran. In summary, 400 persons from participants of the second stage were selected; serum bone turnover markers (bone-specific alkaline phosphatase (bALP), amino-terminal procollagen propeptides of type I collagen (P1NP), osteocalcin (OC), tartrate-resistant acid phosphatase isoenzyme 5b (TRAP)) and vitamin D were measured. Vitamin D deficiency was defined as serum 25(OH) D below 20 ng/ml, and Bone health was considered in terms of Osteoporosis and degraded bone microarchitecture.

The number of partially or significantly degraded microstructure based on TBS was higher than the number of osteoporotic women based on BMD. Women with higher CTX levels were more prone to being degraded microarchitecture. Although we couldn't find any association between vitamin D deficiency and bone health, when we considered the vitamin D levels in univariable modelling, the effect of it was significant.

In this study, only CTX was found to be significantly correlated with TBS while BMD was associated with CTX, OC, and TRAP.

Dual energy X-ray absorptiometry (DXA) was used to analyze body composition, bone mineral density (BMD) parameters and the trabecular bone score (TBS) in patients with obesity before, 3 months after and 1 year after bariatric surgery as a method to evaluate the changes in BMD and skeletal microarchitecture (MA) in patients with obesity after bariatric surgery and to provide a basis for further accurate assessment of the bone health status of this population and subsequent treatment.

This study was a retrospective analysis of 41 patients that underwent DXA imaging before, 3 months after and maximum 1 year after bariatric surgery. The follow-up rate in both periods was 100%. First, the changes in BMD and TBS before and after surgery were compared between patients grouped by sex and obesity degree. Secondly, the correlations between the TBS or BMD and body composition 1 year after surgery were analyzed.

The BMD and TBS were within the normal range after bariatric surgery. Changes in the BMD and TBS were related to time, the degree of obesity and sex. Changes in the TBS were closely related to changes in the BMD, and the trends in the changes in the BMD were basically the same among the different groups of individuals with obesity of different sexes. A negative correlation was observed between the TBS and fat percentage (total body, leg, trunk, android area), as well as the lumbar spine Z-score in patients 1 year after bariatric surgery (p < 0.05).

Bariatric surgery in patients with obesity has no obvious adverse effects on BMD or TBS. DXA can be used to better evaluate the changes in BMD and MA in patients with obesity after bariatric surgery, providing a basis for the clinical evaluation of post-bariatric surgery efficacy in these individuals and subsequent accurate assessment of the bone health status and treatment of this population.

Osteoporosis and metabolic syndrome (MetS) are conditions associated with ageing and chronic inflammation; among MetS' components, visceral obesity has been correlated to low bone mineral density in postmenopausal women. However, data on an increased fracture risk in MetS are still contrasting. The trabecular bone score (TBS) is an indicator of bone quality and a potential predictive factor for fractures. We aim to explore the relationship between MetS components and TBS.

we analyzed data from 3962 women in the 2005-2006 and 2007-2008 NHANES cohorts, for whom a valid TBS value was available. All analyses were adjusted for the principal risk factors of altered bone metabolism.

An inverse significant association was observed between TBS and most of the MetS variables investigated, with the strongest correlation found with waist circumference (WC) (P <0.001). WC represented the major predictor of degraded TBS (P <0.001), in adjusted models considering age, 25(OH)Vitamin D, smoke and insulin resistance. Increased WC was significantly associated with the presence of bone fractures at the logistic regression analysis (P = 0.001) in all study participants and in the subgroup of women ≤50 years old after adjustment for potential confounders (P = 0.006).

This study, using a large sample of women, found a negative association of MetS on bone health, mainly driven by visceral obesity.

Bone strength depends on both bone density and quality. However, the differences in how body composition indices affect bone strength between men and women remains unclear. This study investigated the associations of various fat and lean indices with bone strength by sex. In this cross-sectional study involving 1,419 participants, bone mineral density (BMD) and body composition were measured using dual-energy X-ray absorptiometry. Bone quality was assessed using the trabecular bone score (TBS). Fat indices included total fat mass, body fat percentage, and waist circumference, while lean indices included appendicular lean mass (ALM) and hand grip strength. All fat indices demonstrated a positive association with BMD and a negative association with the TBS in both men and women. Fat indices were more strongly associated with BMD in women than in men. Furthermore, lean indices contributed more to BMD in men than in women. In women, ALM contributed more to BMD than hand grip strength, whereas in men, hand grip strength had a greater impact on BMD than ALM. Hand grip strength was also positively associated with the TBS in men. Overall, fat indices had a greater influence on BMD in women, while lean indices were more positively associated with bone strength in men. Considering different fat indices, ALM was more strongly associated with BMD in women, whereas hand grip strength played a greater role in men. Thus, maintaining both muscle mass and strength is crucial for preserving bone mass.

Studies have shown that the clinical efficacy of TBS (Trabecular Bone Score) of DXA in hip fracture patients. This study aimed to investigate the difference of TBS in trochanteric fractures and femoral neck fractures in hip fracture patients.

Data were derived from the University affiliated hospital, the participants included 249 patients aged 60 years or older who were available of TBS prescribe by DXA. 89 femoral neck fracture patients and 160 trochanteric fractures were enrolled. Spine T- score, hip T- score (neck), hip T- score (total), lowest T- score in hip, L1-L4 TBS. TBS Z-score, L1-L4 BMD(g/cm²), L1-L4 BMD T-score, L1 TBS, L1 BMD(g/cm2), L1 BMD T-score, L2 TBS, L2 BMD(g/cm2), L2 BMD T-score, L3 TBS, L3 BMD(g/cm2), L3 BMD T-score, L4 TBS, L4 BMD(g/cm2), L4 BMD T-score, lowest TBS score, highest TBS score were analyzed.

Demographic data (age, sex, height, weight, BMI) and T-score of hip and spine in two groups showed no significant difference. TBS in spine in two groups revealed higher TBS in femoral neck fracture groups.

There is no difference of age, sex, and BMI in two groups. The T-score was not statistically significant in comparison of bone quality in hip fracture groups. The TBS in femoral neck fracture group is higher than trochanteric fractures. The TBS in spine can be more valuable than T-score of DXA for the proper evaluation of bone quality in the hip fracture patients.